Avails Medical Awarded $2.5M in CARB-X Funding for the Development of its Rapid Antibiotic Susceptibility Testing Device to Identify the Most Effective Antibiotic Therapy
CARB-X is featured.
Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform
CARB-X is featured.
Can We Warp-Speed Antibiotic Development?
Kevin Outterson is quoted.
January 11, 2021 MedCity NewsNon-Profits Fill Gaps in the Broken Market for Antibiotics
CARB-X is featured.
December 10, 2020 Financial TimesCARB-X Wins Prestigious Award for Efforts to Combat Antibiotic-Resistant Bacteria
Kevin Outterson is quoted.
December 10, 2020 Homeland Preparedness NewsClarametyx Biosciences Awarded up to $14.2 Million From CARB-X to Accelerate Novel Immune-Enabling Technology to Combat Persistent Bacterial Infections
Funding agreement fuels development of platform targeting universal structure within biofilms to eliminate bacterial defenses and sensitize to immune or antibiotic intervention.
Kenneth Thorpe and Erik Paulsen: Superbugs Will Kill Millions — Unless Congress Acts
CARB-X is mentioned.
Locus Biosciences signs contract with CARB-X to advance $14 million precision medicine program to develop crPhage™ product targeting Klebsiella pneumoniae infections
MORRISVILLE, N.C., Nov. 10, 2020 /PRNewswire/ –Locus Biosciences, a clinical-stage biopharmaceutical company, announced today that it has signed a contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to fund up to $12.5 million of a $14.8 million program for development of LBP-KP01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product targeting the bacterial pathogen Klebsiella pneumoniae (K. pneumoniae). Read More.
How a Small Biotech Survives Amid Looming Antibiotic Crisis
Kevin Outterson is quoted.
October 26, 2020 MSNWhy Big Pharma has Abandoned Antibiotics
CARB-X is noted.